Due to the distinctly different levels of GSH in tumor cells and physiological conditions, these CPT-prodrug nanoparticles could remain stable under physiological conditions but rapidly release active drugs after uptake by HCC cells with ASGPR-mediated endocytosis, which obtained better HCC curative performances [8,20]. The gene discussed is ASGR1; the disease is hepatocellular carcinoma.